Global Lassa Fever Pipeline Review - Key Players Involved in Therapeutic Development Including Etubics, GeoVax Labs and Zalgen Labs

DUBLIN, April 22, 2020 /PRNewswire/ -- The "Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2020" drug pipelines has been added to's offering.

This Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape. The guide provides comprehensive information on the therapeutics under development for Lassa Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Lassa Fever (Infectious Disease).
    --  The pipeline guide reviews pipeline therapeutics for Lassa Fever
        (Infectious Disease) by companies and universities/research institutes
        based on information derived from company and industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in Lassa Fever
        (Infectious Disease) therapeutics and enlists all their major and minor
    --  The pipeline guide evaluates Lassa Fever (Infectious Disease)
        therapeutics based on mechanism of action (MoA), drug target, route of
        administration (RoA) and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Lassa Fever (Infectious Disease)

Key benefits:

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Lassa Fever (Infectious Disease).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Lassa Fever (Infectious Disease) pipeline depth and focus of Indication
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Key Topics Covered:

    --  Introduction
    --  Report Coverage
    --  Lassa Fever (Lassa Hemorrhagic Fever) - Overview
    --  Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development
    --  Pipeline Overview
    --  Pipeline by Companies
    --  Pipeline by Universities/Institutes
    --  Products under Development by Companies
    --  Products under Development by Universities/Institutes
    --  Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment
    --  Assessment by Target
    --  Assessment by Mechanism of Action
    --  Assessment by Route of Administration
    --  Assessment by Molecule Type
    --  Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in
        Therapeutics Development
    --  R&D Progress
    --  Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects
    --  Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones
    --  Featured News & Press Releases
    --  Appendix

Companies Mentioned

    --  Emergent BioSolutions Inc
    --  Etubics Corp
    --  Fujifilm Toyama Chemical Co Ltd
    --  GeoVax Labs Inc
    --  Inovio Pharmaceuticals Inc
    --  Kineta Inc
    --  Medigen Inc
    --  RetroVirox Inc
    --  Themis Bioscience GmbH
    --  Zalgen Labs LLC

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets